Agilent signs exome agreement with Ambry Genetics
Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services.
'Ambry is intensely focused on delivering the highest quality results for exome sequencing for all of our clients and customers,' said Ardy Arianpour, vice president of business development at Ambry Genetics. 'With Agilent Technologies we have found the ideal partner we can count on in bringing our exome sequencing to market with scalability and speed. With Agilent’s SureSelect, Ambry Genetics is offering whole exome capture services for cancer markers, drug response and Mendelian disease gene discovery. Ambry’s exome sequencing services deliver state of the art bioinformatics which include variant filtering, annotation and interpretation of candidate mutations.'
'Agilent is very excited to partner with Ambry for their exome sequencing needs,' said Kathleen Shelton, Agilent senior marketing director, genomics. 'We believe the quality and consistency SureSelect brings closely complements the level of service provided by Ambry and expected by their customers.'